Skip to Main Content

A pill from Mirati Therapeutics designed to block the cancer protein called KRAS shrank tumors in 45% of patients with advanced lung cancer, according to pooled results from two clinical trials presented Sunday.

The tumor response to the Mirati drug, called adagrasib, is still preliminary, yet it’s also the best and most encouraging data reported so far for an emerging class of treatments that block a cancer target once thought to be “undruggable.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.